ID   KM-H2
AC   CVCL_1330
AS   CVCL_2978
SY   KM H-2; KMH2
DR   BTO; BTO_0004972
DR   CLO; CLO_0007112
DR   CLDB; cl3033
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473401
DR   BioSample; SAMN10988578
DR   cancercelllines; CVCL_1330
DR   Cell_Model_Passport; SIDM01018
DR   ChEMBL-Cells; CHEMBL3308204
DR   ChEMBL-Targets; CHEMBL2366250
DR   Cosmic; 909976
DR   Cosmic; 988704
DR   Cosmic; 1013910
DR   Cosmic; 1086357
DR   Cosmic; 1191707
DR   Cosmic; 1289700
DR   Cosmic; 1290219
DR   Cosmic; 1432041
DR   Cosmic; 2276325
DR   Cosmic; 2361388
DR   Cosmic; 2464308
DR   Cosmic-CLP; 909976
DR   DepMap; ACH-000815
DR   DSMZ; ACC-8
DR   DSMZCellDive; ACC-8
DR   EGA; EGAS00001000978
DR   GDSC; 909976
DR   GEO; GSM335391
DR   GEO; GSM499723
DR   GEO; GSM499731
DR   GEO; GSM552446
DR   GEO; GSM637987
DR   GEO; GSM646533
DR   GEO; GSM887214
DR   GEO; GSM888288
DR   GEO; GSM1669990
DR   IARC_TP53; 21433
DR   IARC_TP53; 23616
DR   IPD-IMGT/HLA; 15116
DR   LiGeA; CCLE_432
DR   LINCS_LDP; LCL-2009
DR   Lonza; 21
DR   PharmacoDB; KMH2_752_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1330
DR   PubChem_Cell_line; CVCL_1330
DR   Wikidata; Q54900048
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2602653;
RX   PubMed=2690233;
RX   PubMed=3013343;
RX   PubMed=3359046;
RX   PubMed=8547074;
RX   PubMed=8558920;
RX   PubMed=11372738;
RX   PubMed=17065008;
RX   PubMed=18194364;
RX   PubMed=19380639;
RX   PubMed=20164919;
RX   PubMed=20628145;
RX   PubMed=21368758;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=25894527;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29533902;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=35839778;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: ~48 hours (DSMZ=ACC-8).
CC   HLA typing: A*24:02; B*15:01,52:01; C*04:01,12:02; DPB1*02:01,05:01; DQA1*03:01,05:05; DQB1*03:01,03:02; DRB1*04:65,11:01; DRB3*02:02; DRB4*01:03 (IPD-IMGT/HLA=15116).
CC   HLA typing: A*11:01,24:02; B*15:01,52:01; C*04:01,12:02; DQA1*03:02,05:01; DQB1*03:03,03:03; DRB1*04:06,11:01 (PubMed=26589293).
CC   HLA typing: A*11:01:01,24:02:01; B*15:01:01,52:01:01; C*04:01:01,12:02:02; DPA1*01:03:01,02:02:02; DPB1*05:01:01,02:01:02; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRA*01:01:01,01:01:01; DRB1*04:06:01,11:01:01 (DSMZCellDive=ACC-8).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; HGNC:11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7067; CIITA + HGNC; HGNC:44654; PIERCE2; Name(s)=CIITA-C15orf65, CIITA-PIERCE2 (PubMed=21368758).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7059; MGMT + HGNC; HGNC:28121; PRRC2B; Name(s)=PRRC2B-MGMT, BAT2L1-MGMT (PubMed=21368758).
CC   Sequence variation: Mutation; HGNC; HGNC:11896; TNFAIP3; Unexplicit; In2-Ex6 del; Zygosity=Heterozygous (PubMed=19380639).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Proteomics; Subcellular; Cell surface.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq virome analysis.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=1.68%; Native American=0%; East Asian, North=78.89%; East Asian, South=17.68%; South Asian=0%; European, North=0%; European, South=1.75% (PubMed=30894373).
CC   Misspelling: KHM2/171877; IPD-IMGT/HLA=15116; Note=In old versions.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP=909976; DSMZ=ACC-8
ST   Amelogenin: X
ST   CSF1PO: 10,14
ST   D13S317: 10,11
ST   D16S539: 9
ST   D18S51: 15
ST   D19S433: 14,16
ST   D21S11: 30,31.2,32.2
ST   D2S1338: 20,24
ST   D3S1358: 15,16
ST   D5S818: 11,13
ST   D7S820: 10,11,12
ST   D8S1179: 10
ST   FGA: 23,24
ST   Penta D: 10,11
ST   Penta E: 15,18
ST   TH01: 7,9
ST   TPOX: 8,10,11,12 (DSMZ=ACC-8)
ST   TPOX: 8,11,12 (Cosmic-CLP=909976)
ST   vWA: 17,18
DI   NCIt; C9357; Hodgkin lymphoma
DI   ORDO; Orphanet_98293; Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 45
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=2602653; DOI=10.1007/978-3-642-83781-4_9;
RA   Kamesaki H., Fukuhara S., Uchino H., Nosaka T.;
RT   "A new hypothesis on the cellular origin of Reed-Sternberg and Hodgkin
RT   cells based on the immunological and molecular genetic analysis of the
RT   KM-H2 line.";
RL   Recent Results Cancer Res. 117:83-90(1989).
//
RX   PubMed=2690233; DOI=10.1007/978-3-642-83781-4_5;
RA   Schaadt M., Burrichter H., Pfreundschuh M., Schell-Frederick E.,
RA   Tesch H., Fonatsch C., Stein H., Diehl V.;
RT   "Biology of Hodgkin cell lines.";
RL   Recent Results Cancer Res. 117:53-61(1989).
//
RX   PubMed=3013343; DOI=10.1182/blood.V68.1.285.285;
RA   Kamesaki H., Fukuhara S., Tatsumi E., Uchino H., Yamabe H., Miwa H.,
RA   Shirakawa S., Hatanaka M., Honjo T.;
RT   "Cytochemical, immunologic, chromosomal, and molecular genetic
RT   analysis of a novel cell line derived from Hodgkin's disease.";
RL   Blood 68:285-292(1986).
//
RX   PubMed=3359046; DOI=10.1182/blood.V71.5.1382.1382;
RA   Hsu S.-M., Zhao X., Chakraborty S., Liu Y.-F., Whang-Peng J.,
RA   Lok M.-S., Fukuhara S.;
RT   "Reed-Sternberg cells in Hodgkin's cell lines HDLM, L-428, and KM-H2
RT   are not actively replicating: lack of bromodeoxyuridine uptake by
RT   multinuclear cells in culture.";
RL   Blood 71:1382-1389(1988).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=11372738; DOI=10.1007/BF02981944;
RA   Uehira K., Amakawa R., Ito T., Uehira T., Ozaki Y., Shimizu T.,
RA   Fujimoto M., Inaba M., Fukuhara S.;
RT   "A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of
RT   dendritic cells and B cells.";
RL   Int. J. Hematol. 73:236-244(2001).
//
RX   PubMed=17065008; DOI=10.1080/10428190600667721;
RA   Feuerborn A., Moritz C., von Bonin F., Dobbelstein M., Trumper L.,
RA   Sturzenhofecker B., Kube D.;
RT   "Dysfunctional p53 deletion mutants in cell lines derived from
RT   Hodgkin's lymphoma.";
RL   Leuk. Lymphoma 47:1932-1940(2006).
//
RX   PubMed=18194364; DOI=10.1111/j.1399-0039.2007.01001.x;
RA   Witter K., Mautner J., Volgger A., Zahn R., Kauke T.;
RT   "A novel HLA-DRB1 allele, HLA-DRB1*0465, was identified in a Hodgkin's
RT   lymphoma cell line.";
RL   Tissue Antigens 71:257-258(2008).
//
RX   PubMed=19380639; DOI=10.1084/jem.20090528; PMCID=PMC2715030;
RA   Schmitz R., Hansmann M.-L., Bohle V., Martin-Subero J.I., Hartmann S.,
RA   Mechtersheimer G., Klapper W., Vater I., Giefing M., Gesk S.,
RA   Stanelle J., Siebert R., Kuppers R.;
RT   "TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and
RT   primary mediastinal B cell lymphoma.";
RL   J. Exp. Med. 206:981-989(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780; PMCID=PMC2995356;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=21368758; DOI=10.1038/nature09754; PMCID=PMC3902849;
RA   Steidl C., Shah S.P., Woolcock B.W., Rui L.-X., Kawahara M., Farinha P.,
RA   Johnson N.A., Zhao Y.-J., Telenius A., Ben-Neriah S., McPherson A.,
RA   Meissner B., Okoye U.C., Diepstra A., van den Berg A., Sun M.,
RA   Leung G., Jones S.J.M., Connors J.M., Huntsman D.G., Savage K.J.,
RA   Rimsza L.M., Horsman D.E., Staudt L.M., Steidl U., Marra M.A.,
RA   Gascoyne R.D.;
RT   "MHC class II transactivator CIITA is a recurrent gene fusion partner
RT   in lymphoid cancers.";
RL   Nature 471:377-381(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:e0121314.1-e0121314.22(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C.,
RA   Yang H.H., Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:e0210404.1-e0210404.22(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218.1-8218.14(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//